Voronoi Inc (310210)

Currency in KRW
170,800
-12,200(-6.67%)
Closed·
310210 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
166,700183,700
52 wk Range
106,500375,500
Key Statistics
Bid/Ask
170,800.00 / 170,900.00
Prev. Close
170,800
Open
181,200
Day's Range
166,700-183,700
52 wk Range
106,500-375,500
Volume
83.38K
Average Volume (3m)
109.28K
1-Year Change
47.7509%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
310210 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
375,000
Upside
+119.56%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Voronoi Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 375,000
(+119.56% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 15, 2026
EPS / Forecast
-1,200.00 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

310210 Income Statement

Compare 310210 to Peers and Sector

Metrics to compare
310210
Peers
Sector
Relationship
P/E Ratio
−60.8x−19.6x−0.4x
PEG Ratio
2.58−0.650.00
Price/Book
33.5x2.9x2.6x
Price / LTM Sales
409.2x26.3x3.0x
Upside (Analyst Target)
119.6%90.2%56.9%
Fair Value Upside
Unlock16.8%9.2%Unlock

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
744.99K4.14%127.24B
Other Institutional Investors
0.000.00%0.00
Public Companies & Retail Investors
17.25M95.86%2.95T
Total
18M100.00%3.07T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC1.79%322,36455,059,771
BlackRock, Inc.1.16%209,15235,723,162

People Also Watch

203,000
010120
-7.31%
883,000
267260
-7.05%
88,700
298380
-6.63%
1,993,000
009150
-0.20%
107,800
007660
-1.64%

FAQ

What Is the Voronoi (310210) Stock Price Today?

The Voronoi stock price today is 170,800 KRW.

What Stock Exchange Does Voronoi Trade On?

Voronoi is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Voronoi?

The stock symbol for Voronoi is "310210."

What Is the Voronoi Market Cap?

As of today, Voronoi market cap is 3.07T KRW.

What Is Voronoi's Earnings Per Share (TTM)?

The Voronoi EPS (TTM) is -2,800.

From a Technical Analysis Perspective, Is 310210 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Voronoi Stock Split?

Voronoi has split 1 times.

How Many Employees Does Voronoi Have?

Voronoi has 140 employees.

What is the current trading status of Voronoi (310210)?

As of Jun 28, 2026, Voronoi (310210) is trading at a price of 170,800 KRW, with a previous close of 170,800 KRW. The stock has fluctuated within a day range of 166,700 KRW to 183,700 KRW, while its 52-week range spans from 106,500 KRW to 375,500 KRW.

What Is Voronoi (310210) Price Target According to Analysts?

The average 12-month price target for Voronoi is 375,000 KRW, with a high estimate of 450000 KRW and a low estimate of 300000 KRW. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +119.56% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.